Key Takeaways
- uniQure held a Pre‑Submission Meeting with the UK’s MHRA on 30 April 2026 and plans to file a Marketing Authorization Application (MAA) for AMT‑130 in Q3 2026.
- The UK filing will rely on three‑year data from the ongoing Phase 1/2 trial, showing roughly a 75 % slowing of Huntington’s disease progression at the high dose.
- The MHRA may grant standard or conditional approval; uniQure has not yet specified which pathway it will pursue.
- In the United States, the FDA deemed the existing Phase 1/2 data insufficient and asked for a new randomized, sham‑controlled Phase 3 trial; a Type B meeting is scheduled for Q2 2026 to discuss trial design and the four‑year data readout expected later in 2026.
- Leadership changes at the FDA’s Center for Biologics Evaluation and Research (CBER) add uncertainty to the US regulatory path, while uniQure continues to explore approval routes in other international markets.
Overview of the MHRA and Pre‑Submission Meetings
The Medicines and Healthcare products Regulatory Agency (MHRA) is the United Kingdom’s authority responsible for evaluating the safety, efficacy, and quality of medicines before they can be prescribed. Functionally, it mirrors the role of the US Food and Drug Administration (FDA). A Pre‑Submission Meeting is an early, informal dialogue between a sponsor and the regulator, held before a formal application is lodged. Its purpose is to verify that the planned data package, manufacturing details, and study designs meet the agency’s expectations, thereby reducing the risk of major deficiencies during the formal review. uniQure described the MHRA’s feedback from its 30 April 2026 meeting as constructive and confirmed that it will proceed to submit a Marketing Authorization Application (MAA) in the third quarter of 2026.
Data Supporting the UK Application
The MAA that uniQure intends to file will be grounded in the three‑year interim results from its ongoing Phase 1/2 clinical trial conducted in the United States and Europe. At this time point, participants who received the high dose of AMT‑130 exhibited an approximate 75 % reduction in the rate of disease progression compared with a natural‑history control group, as measured by the composite Unified Huntington’s Disease Rating Scale (cUHDRS). Although the press release does not explicitly state whether uniQure will seek a standard or conditional authorization, the MHRA does possess a conditional approval mechanism for therapies addressing serious unmet needs—such as Huntington’s disease—should the agency deem the early evidence sufficiently compelling.
Conditional Versus Standard Approval in the UK
Regulatory agencies retain discretion over the type of approval they grant, even when evaluating identical datasets. The MHRA’s conditional pathway permits earlier patient access when a medicine shows promising benefit‑risk balance, contingent on the completion of additional confirmatory studies. uniQure has not yet clarified which route it will pursue; however, the agency’s willingness to engage in a Pre‑Submission Meeting suggests that the sponsor’s data package is viewed as sufficiently robust to move forward. Ultimately, the MHRA will conduct an independent assessment and decide whether to grant a standard Marketing Authorization, a conditional approval, or request further information before reaching a decision.
Current Status of the US Regulatory Path
In contrast to the UK progress, the US regulatory journey for AMT‑130 has encountered significant hurdles. Earlier in 2026, the FDA informed uniQure that the existing Phase 1/2 data are inadequate to support approval and recommended conducting a new randomized, sham‑controlled Phase 3 trial. In response, uniQure secured a Type B meeting with the FDA slated for the second quarter of 2026, where sponsors and regulators will discuss potential Phase 3 trial designs and the statistical analysis plan for the forthcoming four‑year data readout, expected in Q3 2026. This meeting represents a critical opportunity to align on the evidence needed for a US marketing application.
Impact of FDA Leadership Changes
Adding another layer of complexity, the leadership of the FDA’s Center for Biologics Evaluation and Research (CBER)—the division that oversees gene‑therapy products like AMT‑130—has recently changed. Dr. Vinay Prasad, who had directed CBER during the period when the agency urged a sham‑controlled trial and expressed skepticism toward cell‑based therapies, departed the FDA on 30 April 2026 to return to academia at the University of California, San Francisco. Dr. Katherine Szarama, previously Prasad’s deputy, has been appointed acting CBER director. Her perspectives on gene‑therapy evaluation standards, and specifically on AMT‑130, have not yet been made public, and a permanent replacement has not been named. Consequently, the trajectory of the US review remains uncertain and will be closely monitored as the new leadership settles in.
Why Divergent Outcomes Are Possible
It is important to recognize that different regulatory bodies can reach distinct conclusions from the same scientific evidence. The MHRA operates under its own statutory framework, risk‑benefit appraisal methods, and precedent, which may lead it to view the three‑year data as sufficient for approval—either standard or conditional—whereas the FDA has concluded that more rigorous evidence is required. This divergence does not imply inconsistency in the science; rather, it reflects the autonomy of each agency to tailor its decision‑making process to the public‑health priorities and legal standards of its jurisdiction.
Implications for the Huntington’s Disease Community
For patients and families in the United Kingdom and elsewhere, uniQure’s intention to file an MAA marks a meaningful advance toward potential access to a disease‑modifying therapy. The company has also indicated that it is actively pursuing regulatory pathways in additional international markets, with further updates anticipated in the second half of 2026. In the United States, the outlook is more nuanced: while the current data set is deemed insufficient by the FDA, the upcoming Type B meeting and the anticipated four‑year readout keep the possibility of approval alive. Stakeholders should remain engaged, as both the UK and US pathways continue to evolve and may ultimately shape the availability of AMT‑130 for the broader Huntington’s disease community.